Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 5/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551392 | 1.00 | HTT (0.52) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL116193 | 0.84 | HTT (0.48) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL23619926 | 0.80 | NR4A2 (0.49) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL30908153 | 0.80 | ALDH1A1 (0.48) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL31606740 | 0.80 | NR4A2 (0.62) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL3454205 | 0.80 | NR4A2 (0.49) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL3711428 | 0.80 | KDM4E (0.45) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL18318260 | 0.80 | ALDH1A1 (0.48) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL22719670 | 0.80 | KDM4E (0.53) | HTTCYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL14659006 | 0.80 | HTT (0.48) | HTTCYP1A2CYP2C19KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457243-B | Synthesis method of 7-bromo-5-methoxyquinoline | 苏州康润医药有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112457243-A | Synthesis method of 7-bromo-5-methoxyquinoline | 苏州康润医药有限公司 | 2021-03-09 | — | — | CN | claimed |
| CN-110041905-B | Fluorescent and phosphorescent dual luminescent material with switching effect and preparation method thereof | 华中科技大学 | 2020-05-19 | — | — | CN | claimed |
| WO-2009140215-A2 | METHOD FOR TREATING DRUG-RESISTANT BACTERIAL AND OTHER INFECTIONS WITH CLIOQUINOL, PHANQUINONE, AND RELATED COMPOUNDS | GERAGHTY, ERIN (US) | 2009-11-19 | — | — | WO | claimed |
| US-20080207673-A1 | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins | XILINAS MICHEL | 2008-08-28 | — | — | US | claimed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | claimed |
| EP-4079724-B1 | 2-(2-CHLOROPHENYL)-N-(5-SULFAMOYLISOQUINOLIN-7-YL)ACETAMIDE DERIVATIVES AND SIMILAR COMPOUNDS AS P2X4 ANTAGONISTS FOR THE TREATMENT OF E.G. URINARY TRACT DISEASES | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| CN-114901642-B | Fused ring compound and application thereof | 武汉朗来科技发展有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| WO-2006117660-A2 | METHOD FOR TREATING CANCER, CORONARY, INFLAMMATORY AND MACULAR DISEASE, COMBINING THE MODULATION OF ZINC- AND/OR COPPER DEPENDENT PROTEINS | CLIO PHARMACEUTICAL CORPORATION (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2002051415-A2 | USE OF SEQUESTRANTS FOR TREATING PRION DISEASES | XILINAS MICHEL (CY) | 2002-07-04 | — | — | WO | disclosed |
| EP-0138773-B1 | USE OF QUINOLINE DERIVATIVES FOR THE PROTECTION OF CROP PLANTS | CIBA-GEIGY AG (CH) | 1990-08-29 | — | — | EP | disclosed |
| US-4749406-A | Quinoline derivatives and compositions thereof for the protection of cultivated plants | CIBA-GEIGY CORPORATION (US) | 1988-06-07 | — | — | US | disclosed |
| US-4585472-A | PRE- AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1986-04-29 | — | — | US | disclosed |
| EP-0138773-A2 | Use of quinoline derivatives for the protection of crop plants | CIBA-GEIGY AG (CH) | 1985-04-24 | — | — | EP | disclosed |
| EP-0102542-A2 | 1,2,4,6-Thiatriazin-1,1-dioxide ethers, process for their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | HTT 2671/4885CYP1A2 657/4885CYP2C19 517/4885 |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HTT 2553/4885CYP1A2 2421/4885CYP2C19 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.